iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
iNtRON Biotechnology Inc (048530) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.013x
Based on the latest financial reports, iNtRON Biotechnology Inc (048530) has a cash flow conversion efficiency ratio of -0.013x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-993.53 Million) by net assets (₩73.98 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
iNtRON Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how iNtRON Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
iNtRON Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iNtRON Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arcelik AS
IS:ARCLK
|
0.334x |
|
Simplex Infrastructures Limited
NSE:SIMPLEXINF
|
0.222x |
|
Semperit AG Holding
LSE:0G29
|
0.037x |
|
Charlton Aria Acquisition Corporation Units
NASDAQ:CHARU
|
0.000x |
|
eToro Group Ltd.
NASDAQ:ETOR
|
0.030x |
|
SELECTQUOTE INC. DL -01
F:6SJA
|
N/A |
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
-0.049x |
|
Webjet Group Ltd
AU:WJL
|
0.133x |
Annual Cash Flow Conversion Efficiency for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of iNtRON Biotechnology Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩83.77 Billion | ₩-138.47 Million | -0.002x | -105.13% |
| 2023-12-31 | ₩96.73 Billion | ₩3.12 Billion | 0.032x | -42.74% |
| 2022-12-31 | ₩106.18 Billion | ₩5.98 Billion | 0.056x | -65.37% |
| 2021-12-31 | ₩101.35 Billion | ₩16.47 Billion | 0.163x | +94.60% |
| 2020-12-31 | ₩85.38 Billion | ₩7.13 Billion | 0.084x | +767.82% |
| 2019-12-31 | ₩64.96 Billion | ₩-812.48 Million | -0.013x | -111.64% |
| 2018-12-31 | ₩39.09 Billion | ₩4.20 Billion | 0.107x | +159.44% |
| 2017-12-31 | ₩30.24 Billion | ₩-5.47 Billion | -0.181x | -91.32% |
| 2016-12-31 | ₩49.15 Billion | ₩-4.64 Billion | -0.094x | -291.53% |
| 2015-12-31 | ₩34.44 Billion | ₩1.70 Billion | 0.049x | +277.79% |
| 2012-12-31 | ₩11.93 Billion | ₩-331.01 Million | -0.028x | -- |